Drugs / SPARC1613
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03109249 Comparator | Jan 2017 → Oct 2018 | breast cancer | Sun Pharma Advanced Research Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPARC1613 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03109249 ↗ |
| Route | Intravenous | “Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes” NCT03109249 ↗ |